Drug intelligence / Profile preview

MC-4001

Development stage: Preclinical
Lead developer: MacuCLEAR
Modality: Small Molecules
Administration: Ophthalmic

Overview

MC-4001 is a preclinical-stage drug candidate being developed by MacuCLEAR, Inc. for the treatment of diabetic eye diseases, including diabetic retinopathy and other vascular diseases of the eye. It functions as an interleukin-1 (IL-1) inhibitor that specifically targets the interleukin-1 receptor 1 (IL1R1). By antagonizing IL1R1, MC-4001 aims to mitigate the inflammatory and vascular damage associated with chronic retinal conditions. The drug is part of MacuCLEAR's broader pipeline of ocular therapies, which focuses on addressing vascular and retinal diseases through targeted pharmacological intervention.

Targets

IL1R1 (Interleukin-1 Receptor Type 1)

Beyond the preview

Go deeper on MC-4001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MC-4001.

Explore the full profile